ANP
(aka atrial natriuretic peptide, ANF, atrial natriuretic factor)

Chemical formula: C127H205N45O39S3

Properties:
Cardiac hormone, major role in lowering blood pressure and inhibiting aldosterone

Studies:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496260

https://pubmed.ncbi.nlm.nih.gov/2932646

https://pubmed.ncbi.nlm.nih.gov/6092045

https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/atrial-natriuretic-factor

ANP_ANF_dwell60-square-384kHz.flac

Sonic chemistry, bioacoustics, medbeds, cymatics, and sound therapy

All tracks are experimental. Treat this as a science project for educational, research, and entertainment purposes. No medical claims are made.

Join QuantaLab on Telegram:
https://t.me/quantalab

QuantaLab Healing Library:      
https://t.me/+IBi3iE5sYUUzYjA5

Daniel DeNeui is an acclaimed entrepreneur and executive who has demonstrated profound expertise in strategic planning, business development, and executive leadership. His skills extend into executive sales coaching, human behavior, psychology, and public speaking. Throughout his career, he has successfully established and scaled multiple businesses into multi-million dollar entities, starting with bootstrap capital.

Currently serving as the Chief Executive Officer of EVEXIAS Health Solutions®, Daniel is pioneering medical wellness by revolutionizing how practitioners approach and practice medicine. His leadership is characterized by innovative strategies integrating scientific research with practical business applications, significantly advancing healthcare.

Under his guidance, alongside his spouse, he directs the strategic vision of the EVEXIAS-FarmaKeio organization, striving to transform healthcare by broadening access to innovative educational and therapeutic solutions. Since being appointed CEO in 2015, he has leveraged his extensive background in science and business to enhance the organization's offerings, including spearheading the development of the EvexiPEL® Method, PeptideSolutions™, and NutraceuticalSolutions™.

Daniel's commitment at EVEXIAS focuses on developing personalized wellness plans incorporating an integrative and functional approach. These plans are meticulously designed to address the root causes of health issues, particularly treating symptoms of hormone imbalances through advanced treatments like bioidentical hormone replacement therapy and specialized nutraceutical supplements.

Daniel's visionary leadership has also facilitated significant technological advancements within the organization. In 2022, he launched EVEXIAS Online, a cutting-edge platform that enhances educational and collaborative opportunities among healthcare professionals. His initiative continued into early 2023 when he led the most extensive training session in the company's history, focusing on practical skills in hormone therapy applications.

Before his role at EVEXIAS, Daniel held key executive positions at Asperio Labs and BioTE Medical, where he focused on hormone optimization and promoting healthy aging. His previous leadership roles at Independent Producers of America and Cornerstone America were instrumental in developing strategic sales initiatives and expanding business operations.

Daniel DeNeui's academic background in organic chemistry from Clemson University has underpinned his professional achievements and innovative approaches in business and healthcare. Beyond his professional life, he enjoys traveling, maintaining an active and healthy lifestyle, and participating in philanthropic efforts to support families facing unexpected challenges.